Excitatory amino acids (e.g., glutamate) released by contraction-activated skeletal muscle afferents into the dorsal horn of the spinal cord initiate the central component of the exercise pressor reflex (EPR) in physiological conditions. However, the role of glutamate and glutamate receptors in mediating the exaggerated EPR in the chronic heart failure (CHF) state remains to be determined. In the present study, we performed microinjection of glutamate receptor antagonists into ipisilateral L4/L5 dorsal horns to investigate their effects on the pressor response to static contraction induced by stimulation of the peripheral end of L4/L5 ventral roots in decerebrate sham-operated (sham) and CHF rats. Microinjection of glutamate (10 mM, 100 nl) into the L4 or L5 dorsal horn caused a greater pressor response in CHF rats compared with sham rats. Furthermore, microinjection of either the broadspectrum glutamate receptor antagonist kynurenate (10 mM, 100 nl) or the N-methyl-D-aspartate (NMDA) receptor antagonist DL-2-amino-5-phosphonovalerate (50 mM, 100 nl) or the non-NMDA-sensitive receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (5 mM, 100 nl) into L4/5 dorsal horns decreased the pressor response to static contraction in CHF rats to a greater extent than in sham rats. Molecular evidence showed that the protein expression of glutamate receptors (both non-NMDA and NMDA) was elevated in the dorsal horn of the lumbar spinal cord in CHF rats. In addition, data from microdialysis experiments demonstrated that although basal glutamate release at the dorsal horn at rest was similar between sham and CHF rats (225 Ϯ 50 vs. 260 Ϯ 63 nM in sham vs. CHF rats, n ϭ 4, P Ͼ 0.05), CHF rats exhibit greater glutamate release into the dorsal horn during muscle contraction compared with sham rats (549 Ϯ 60 vs. 980 Ϯ 65 nM in sham vs. CHF rats, n ϭ 4, P Ͻ 0.01). These data indicate that the spinal glutamate system contributes to the exaggerated EPR in the CHF state. exercise; neurotransmitter; sympathetic nerve activity; blood pressure; decerebration A HALLMARK OF PATIENTS suffering from chronic heart failure (CHF) is sympathoexcitation and exercise intolerance (4, 6, 28, 37) . Even during moderate exercise, extreme activation of the sympathetic nervous system causes an exaggerated pressor response and hyperventilation. Although the mechanisms responsible for the increase in sympathetic outflow and exercise intolerance in CHF are not known, it has been suggested that this may be due, in part, to an exaggerated exercise pressor reflex (EPR) (7, 21, 26) .
The EPR is a peripheral neural reflex originating in skeletal muscle that contributes significantly to the regulation of the cardiovascular system during exercise. The afferent arm of this reflex is composed of metabolically sensitive (predominantly group IV, C-fibers) and mechanically sensitive (predominately group III, A␦-fibers) fibers (5, 13, 16) . Evidence from animal studies has demonstrated that increases in heart rate (HR), arterial pressure, and sympathetic nerve activity in response to activation of this reflex are enhanced in rats with CHF induced by myocardial infarction (MI) (14, 23, 24, 26, 32) . However, the mechanisms underlying the exaggerated EPR in the CHF state are not fully understood. For instance, it is not yet clear which components of the muscle reflex arc mediate the exaggerated EPR in the CHF state. In a recent study (30) , we provided direct evidence that a peripheral sensitization of skeletal muscle afferents contributes to the exaggerated EPR in the CHF state. However, whether central sensitization is also involved in the genesis of the exaggerated EPR in CHF has not been determined.
The dorsal horn of the spinal cord serves as the first central synapse for afferent fibers from skeletal muscle. Neurotransmitters and neuromodulators released by contraction-activated group III and IV muscle afferents into this region initiate the central component of the EPR. Evidence suggests that transmission at the level of the dorsal horn is mainly mediated by excitatory amino acids (e.g., glutamate) (1, 8, 10, 11, 38) . However, whether the spinal cord and its neurotransmitters, particularly glutamate, are involved in the genesis of the exaggerated EPR in CHF has not been evaluated. The primary goal of the present study was to explore the role of the spinal glutamatergic system in mediating the exaggerated EPR at the level of the dorsal horn in CHF. We hypothesized that the exaggerated EPR in CHF is associated with increased glutamatergic activity in the spinal cord.
METHODS
Experiments were performed on male Sprague-Dawley rats weighing ϳ400 -520 g. These experiments were approved by the Institutional Animal Care and Use Committee of the University of Nebraska Medical Center and were carried out under the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Model of CHF. CHF was produced by left coronary artery ligation. These procedures have been described in our previous studies (30, 32) . Briefly, the rat was ventilated at a rate of 60 breaths/min with 3% isoflurane during the surgical procedure. A left thoracotomy was performed through the fifth intercostal space, the pericardium was opened, the heart was exteriorized, and the left anterior descending coronary artery was ligated. Sham-operated (sham) rats were prepared in the same manner but did not undergo coronary artery ligation. All sham rats survived from the surgery. However, ϳ70% of rats survived the coronary artery ligation surgery.
Cardiac function was measured by echocardiography (VEVO 770, Visual Sonics) as previously described (30 -32, 34 ) in all animals 6 wk post-MI. In addition, at the beginning of the acute experiments (9 -11 wk post-MI), a Millar catheter (SPR 524, size: 3.5-Fr, Millar Instruments, Houston, TX) was advanced through the right carotid artery into the left ventricle (LV) to determine LV end-diastolic pressure (LVEDP), LV systolic pressure (LVSP), the maximum first derivative of LV pressure (dP/dt max), and the minimum first derivative of LV pressure (dP/dt min). The transducer was then pulled back into the aorta and left in place to record arterial pressure. After the acute terminal experiments, rats were euthanized with an overdose of pentobarbital sodium. The hearts and lungs were removed, and the ratio of the infarct area to the whole LV minus septum was measured.
Acute surgical preparation. Rats were initially anesthetized with isoflurane (Halocarbon Labs, River Edge, NY, 5% in O 2). A jugular vein and the trachea were cannulated. After tracheal cannulation, the lungs were ventilated with an anesthetic mixture of 2-3% isoflourane and O 2. The right carotid artery was cannulated for measurements of arterial pressure, mean arterial pressure (MAP), and HR. Body temperature was maintained between 37 and 38°C by a heating pad.
Decerebration. The decerebration procedure was performed as previously described by us and others (25, 32, 33) . Briefly, under isoflourane anesthesia, rats were placed in a stereotaxic apparatus (Stoelting, Chicago, IL) and customized spinal frame. Dexamethasone (0.2 mg iv) was given to reduce brain edema and inflammatory responses from the decerebration. The remaining intact carotid artery was isolated and ligated to reduce bleeding during decerebration. Subsequently, a portion of bone superior to the central sagittal sinus was removed. The cerebral cortex was gently aspirated to visualize the superior and inferior colliculi. Using a blunt instrument, the brain was perpendicularly sectioned precollicularly and the transected was forebrain aspirated. A minimum recovery period of 1.25 h was used afte decerebration before any data were acquired.
Activation of the EPR. To activate both mechanically and metabolically sensitive skeletal muscle afferent fibers, static hindlimb contraction was induced by electrical stimulation of the ventral roots. A laminectomy exposing the lower lumbar portions of the spinal cord (L2-L6) was performed, and electrically induced static muscle contraction of the triceps surae was achieved by stimulating the peripheral end of L4/L5 ventral roots for 30 s. Constant-current stimulation was used at three times motor threshold (defined as the minimum current required to produce a muscle twitch) with a pulse duration of 0.1 ms at 40 Hz. All muscles of the hindlimb undergoing study were denervated except for the triceps surae muscle.
Microinjection into the L4/L5 dorsal horn. An additional laminectomy (T11-L2) was performed for the L4/L5 dorsal horn microinjection experiments. Dorsal horn microinjections were made from a four-barrel micropipette and performed by a four-channel pressure injector (PM2000B, World Precision Instruments). The procedure for microinjection in the dorsal horn of the spinal cord was similar to that performed in brain nuclei, such as the rostral ventrolateral medulla, as previously described (35, 36) . Briefly, a four-barrel micropipette (diameter: 20 -30 m) was placed in the dorsal horn of the spinal segment in which the L4/L5 dorsal roots enter. The coordinates of the dorsal horn in this study ranged from 0.4 -0.6 mm lateral to the midline of spinal cord and 0.3-0.5 mm from the dorsal surface of the spinal cord. In all spinal microinjection experiments, one barrel of the pipette was filled with 2% Pontamine sky blue to mark the injection site. Figure 1 shows a representative slice and injection site.
To determine if postsynaptic neuronal sensitization of the EPR occurs in the dorsal horn in the CHF state, we carried out direct microinjections of glutamate (10 mM, 100 nl) into the dorsal horn (L4/L5 segments) and compared responses with those of sham rats. Injections in each segment were made over an ϳ5-to 8-s period at a 100-nl injection volume, which was measured under direct vision by observing the movement of the fluid meniscus along a reticule in a microscope. The time interval between L4 and L5 segment injections was 15-20 min.
In another set of experiments, we performed microinjection of several ionotropic glutamate receptor antagonists, including kynurenate (KYN; 10 mM, 100 nl) (35, 36), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 5 mM, 100 nl) (36) , and DL-2-amino-5-phosphonopentanoic acid (AP5; 50 mM, 100 nl) (36) into the L4/L5 dorsal horn to investigate their effects on the pressor response to static contraction induced by electrical stimulation of L4/L5 ventral roots in sham and CHF rats. CNQX was chosen as the antagonist for ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors based on its specificity to block the respective receptor agonist, whereas AP5 was chosen as the antagonist for N-methyl-D-aspartate (NMDA) receptors. KYN is a broad-spectrum glutamate receptor antagonist. CNQX, AP5, and KYN microinjections were performed in separate animals. L-Glutamate, AP5, CNQX, and KYN were purchased from Sigma-Aldrich (St. Louis, MO). L-Glutamate, AP5, and KYN were dissolved in artificial cerebrospinal fluid (aCSF). In the case of KYN, pH was adjusted to 7.4 -7.6 with 1 M NaOH. CNQX was initially dissolved in 0.1 M phosphate buffer solution and then diluted in aCSF to the final concentration. For each antagonist, the time interval between L4 and L5 segment injections was within 2 min.
Microdialysis. To compare spinal glutamate release during muscle contraction between sham and CHF rats, spinal microdialysis fluid during a 4-min repeated static contraction (30-s on and 30-s off) was collected using a microdialysis probe and quantified by HPLC techniques. Briefly, under isoflourane anesthesia, rats were placed in a stereotaxic instrument and secured within the spinal adaptor by clamps placed on rostral lumbar vertebrae. After decerebration, a Kopf carrier was used to vertically insert a microdialysis probe (0.24 mm in diameter, 1 mm in membrane length, model CMA/11 14/01 Cupr) ϳ1 mm into the dorsal horn of the spinal cord ipsilateral to the contracting hindlimb 1.5 h before the study. The probe was placed perpendicular to the dorsal surface of the spinal cord and approximately midway to the rostrocaudal extent of the dorsal horn at L5. The probe remained attached to the carrier, maintaining the site of insertion relative to the dorsal horn, throughout the experiment. The probe was perfused continuously at a rate of 5 l/min with artificial extracellular fluid buffered to pH 7.4. Extracellular fluid, which was made fresh for each experiment, contained 0.2% BSA, 0.1% bacitracin, and the following ions (in mM): 6. . After a 1.5-h stabilization period, spinal microdialysis samples were first collected during a 4-min noncontracting period (basal) followed by a 4-min repeated static contraction (30-s on and 30-s off, contraction phase). Fifteen minutes after contraction, an additional 4-min sample collection (recovery phase) was performed. All samples were collected in 250-l microcentrifuge tubes, immediately sealed, and stored at Ϫ80°C until analysis.
For HPLC measurements, amino acids were derivatized with ophthaldialdehyde (OPA) reagent and separated by reverse-phase HPLC coupled with fluorescence detection. The OPA reagent was freshly prepared by sonicating 5 mg OPA in 100 l methanol and 5 l ␤-mercaptoethanol. After sonication, 9.9 ml of 1% borate buffer were added. Freshly prepared OPA reagent (100 l) was mixed with 20 l perfusate and 100 l methanol and permitted to react for 30 min at room temperature; 50 l or this reaction were injected onto a 4.6 ϫ 150-mm Eclipse-Plus C18 column (Agilent Technologies) and eluted at a flow rate of 1.2 ml/min with a gradient formed by 5 mM potassium phosphate buffer (pH 7; buffer A) and methanol (buffer B). The 20-min gradient consisted of 10% buffer B for 1.9 min, increasing to 57% buffer B (at 12.1 min), increasing to 100% buffer B (at 16.3 min), and holding at 100% buffer B until 18.2 min, and returning to 10% buffer B at 20 min. OPA-amino acids were detected by fluorescence (excitation: 340 nm and emission: 455 nm). Quantization was done by a comparison of individual peak areas with that of a norleucine internal standard (1 nmol).
Western blot analysis. For Western blot analysis, rats (n ϭ 6 rats/group) were initially anesthetized with an anesthetic mixture of 2-3% isoflourane and O 2. Hemodynamic parameters such as MAP, HR, LVEDP, dP/dtmax, and dP/dtmin were first determined. Rats were then euthanized with an overdose of pentobarbital sodium (150 mg/kg iv). L4/L5 dorsal root ganglia were rapidly removed and lysed with 20 mM Tris·HCl buffer (pH 8.0) containing 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.1% ␤-mercaptoethanol, 0.5 mM DTT, and a mixture of proteinase and phosphatase inhibitors (SigmaAldrich). The hearts and lungs were removed, and infarct size was measured as described above. Protein concentration was measured by the BCA protein assay using BSA as the standard. Proteins were loaded onto a 10% SDS-PAGE gel along with protein standards (Bio-Rad Laboratories) in a separate lane for electrophoresis and then transferred to a polyvinylidene fluoride membrane. The membrane was probed with rabbit polyclonal antibody against glutamate receptor 1 (AMPA; 1:1,000 dilution, Abcam) or NMDA receptor 1 (NR1; 1:1,000 dilution, Abcam) and secondary antibody (goat anti-rabbit IgG, 1:5,000 dilution, Pierce Chemical). Protein signals were detected by enhanced chemiluminescence reagent (Pierce Chemical) and analyzed using UVP BioImaging Systems. GAPDH (1:1,000, Santa Cruz Biotechnology) was used to verify equal protein loading, and the densitometric results of AMPA and NR1 receptors are reported as ratios to GAPDH.
Immunohistochemistry. Rats (n ϭ 5 rats/group) were perfused through the aorta first with 100 ml heparinized saline followed by 500 ml of 4% paraformaldehyde in 0.1 mol/l PBS (pH 7.4). The lumbar spinal cord was immediately dissected and immersed in 4% paraformaldehyde in 0.1 mol/l PBS (pH 7.2) overnight at 4°C. Tissues were then transferred to 30% sucrose in PBS and kept in the solution until they sank to the bottom. Thereafter, the blocks were rapidly frozen, and 20-m sections were cut on a Leica cryostat and thawed onto gelatin-coated slides.
For triple immunostaining of glutamate receptors, sections were stained with isolectin IB4 (a C-fiber neuronal marker) (29) and NeuN (a neuronal marker) (3, 20) . Sections were then washed with PBS and incubated with fluorescence-conjugated secondary antibody (Alexa 488-conjugated goat anti-rabbit IgG and Pacific blue-conjugated goat anti-mouse IgG, 1:200, Invitrogen) and Alexa fluorR 568-conjugated isolectin-B4 (1:200, Invitrogen) for 60 min at room temperature. After three washes with PBS, sections were mounted on precleaned microscope slides. Slides were observed under a Leica fluorescent microscope with corresponding filters. Pictures were captured by a digital camera system. No staining was seen when a negative control was performed with PBS instead of the primary antibody (data not shown).
Data acquisition and statistical analysis. MAP, HR, and muscle tension were acquired using PowerLab software (AD Instruments). Baseline values were determined by analyzing at least 30 s of data before muscle contraction. The peak response was determined in the period of the greatest change from baseline. The tension-time index (TTI) was calculated by integrating the area between the tension trace and the baseline level (expressed in kg·s). Peak developed tension was calculated by subtracting the resting tension from the peak tension (expressed in g). All values are expressed as means Ϯ SE. Differences between groups were determined by two-way ANOVA followed by a Tukey post hoc test. Changes in MAP, HR, TTI, and peak developed tension before and after spinal administration of chemicals were determined by a paired t-test. P values of Ͻ0.05 were considered statistically significant.
RESULTS
Evaluation of body weight, organ weight, and baseline hemodynamics. Echocardiographic and hemodynamic measurements of sham and CHF rats are shown in Table 1 . MI-induced cardiac dilation in CHF rats was indicated by increased LV systolic and diastolic diameters and volumes measured by echocardiography at the sixth week post-MI. Interestingly, echocardiographic data demonstrated that MI rats exhibited an increased absolute value for stroke volume and cardiac output, which we believe is due to a state of compensated heart failure at this time point. Nevertheless, these 6-wk post-MI rats still exhibited reduced ejection fraction and fractional shortening compared with sham rats, indicating decreased cardiac systolic function at this period. Hemodynamic data collected at the time of the terminal experiments (9 -11 wk) further demonstrated that there was a significant increase in LVEDP in CHF rats compared with sham rats, indicating decreased cardiac diastolic function. Heart weightto-body weight and lung weight-to-body weight ratios were significantly higher in CHF rats than in sham rats, suggesting cardiac hypertrophy and substantial pulmonary congestion in the CHF state. Moreover, in rats with CHF, a gross examination revealed a dense scar in the anterior ventricular wall. The mean infarct area was 40.8 Ϯ 0.5% of the LV area. No infarcts were identified in sham rats. Pleural fluid and ascites were also found in some CHF rats but none in sham rats. Compared with sham rats, there was a slight but significant decrease in baseline MAP in CHF rats.
Glutamate release into the dorsal horn is increased during muscle contraction in CHF rats. In a previous study (30) , we reported that CHF rats have increased afferent activity during muscle contraction compared with sham rats. Based on this finding, we hypothesized that the increased muscle afferent activity during contraction will evoke greater glutamate release from the afferent terminals into the dorsal horn in CHF rats. To test this hypothesis, we used in vivo microdialysis to collect extracellular fluid in the L5 dorsal horn before, during, and after a 4-min intermittent muscle contraction in sham and CHF rats. Muscle contraction increased glutamate release into the dorsal horn of sham rats (Fig. 2) . However, glutamate release induced by muscle contraction was greater in CHF rats compared with sham rats.
Cardiovascular responses to direct microinjection of glutamate receptor agonist into the dorsal horn. We carried out microinjection of glutamate into the dorsal horn (L4/L5 segments) to investigate the pressor response to glutamate injection in sham and CHF rats. This technique bypassed the presynaptic afferent terminals to directly determine if postsynaptic neuronal sensitization of the EPR occurs in the dorsal horn in the CHF state. As shown in Fig. 3 , microinjection of glutamate (10 mM, 100 nl) into the L4 or L5 dorsal horn caused a significant pressor response in decerebrate rats. Furthermore, the pressor response to microinjection of glutamate into the L4 or L5 dorsal horn was greater in CHF rats compared with sham rats, suggesting postsynaptic neuronal sensitization in the spinal cord of CHF rats.
Effects of microinjection of glutamate receptor antagonists into the dorsal horn on the EPR.
We also performed dorsal horn microinjection of several ionotropic glutamate receptor antagonists, the broad-spectrum glutamate receptor antagonist KYN, the non-NMDA receptor antagonist CNQX, and the NMDA receptor antagonist AP5, to investigate their effects on the pressor response to static contraction induced by electrical stimulation of L4/L5 ventral roots in decerebrate sham and CHF rats. Figures 4 and 5 show that treatment with these antagonists decreased the pressor response to static contraction in CHF rats to a greater extent than in sham rats, indicating that both non-NMDA and NMDA receptors in the L4/L5 dorsal horn contribute to the central sensitization of the exaggerated EPR in the CHF state. Microinjection of aCSF (vehicle) into the L4/L5 dorsal horn had no effect on the pressor response to static contraction in both sham and CHF rats (Fig. 5A) . Microinjection of all these antagonists or vehicle into the L4/L5 dorsal horn had no effect on basal blood pressure or HR in sham and CHF rats ( Table 2) .
Protein expression of non-NMDA and NMDA receptors in the dorsal horn of sham and CHF rats. Data from both Western blot analysis and immunofluorescence experiments showed that both non-NMDA (AMPA) and NMDA (NR1) receptors in the lumbar dorsal horn are upregulated in CHF rats compared with sham rats (Figs. 6-8 ). Immunofluorescence data (Fig. 8) further indicated that although increased AMPA and NR1 receptors were distributed throughout the entire dorsal horn of CHF rats, AMPA receptors were more intense in deep layers (lamina IV-VI) of the dorsal horn, whereas NR1 receptors were more intense in superficial layers (lamina I-III), which costained with the C-fiber terminal marker IB4. Furthermore, our data demonstrated that the increased spinal AMPAand NR1-positive staining in CHF rats did not completely overlap with NeuN-positive staining, suggesting that increased glutamatergic receptors may occur in both spinal neurons and non-neuronal cell types, such as afferent nerve terminals and astrocytes.
Muscle tension produced by static contraction. In the present study, muscle peak developed tension induced by static contraction ranged from 700 to 800 g in all groups. There was no significant difference in TTI during either static contraction between groups (Table 3) .
DISCUSSION
The primary findings in the present study demonstrate that CHF rats exhibit greater glutamate release in the dorsal horn during muscle contraction compared with sham rats. Most importantly, we found that 1) microinjection of exogenous glutamate into the dorsal horn of the lumbar spinal cord caused a greater pressor response in CHF rats than in sham rats; 2) microinjection of several glutamate receptor antagonists (KYN, AP5, and CNQX) into L4/5 dorsal horns decreased the pressor response to static contraction in CHF rats to a greater extent than in sham rats; and 3) molecular evidence showed that glutamatergic receptors (both AMPA and NMDA) are upregulated in the dorsal horn of the lumbar spinal cord in CHF rats compared with sham rats. To our knowledge, these are the first data providing evidence that spinal sensitization mediated by glutamatergic receptors (both AMPA and NMDA) contributes to the genesis of the exaggerated EPR in CHF.
Although evidence from experimental and clinical studies (14, 18, 22, 24) suggested that the EPR is exaggerated in the CHF state, very few studies have focused on the components of the muscle reflex arc that is altered in the CHF state. In a recent study (35) , we demonstrated that the sensitivity of muscle group III afferents (mainly mechanically sensitive) in response to either muscle contraction or passive stretch is enhanced in CHF rats compared with sham rats, whereas the sensitivity of muscle group IV afferents (mainly metabolically sensitive) in response to either muscle contraction or chemical stimulation (capsaicin) is blunted, which provided direct evidence that a peripheral sensitization of skeletal muscle mechanical afferents contributes to the exaggerated EPR in the CHF state. Based on this finding, it is very likely that at the level of the spinal cord, the dorsal horn, which serves as the first central synapse for afferent fibers from skeletal muscle, may release more excitatory neurotransmitters (e.g., glutamate) to activate spinal postsynaptic neurons as a result of increased peripheral muscle afferent input during acute exercise in CHF. Using the technique of in vivo microdialysis, we demonstrated that CHF rats have greater glutamate release in the dorsal horn during muscle contraction compared with sham rats, which provides strong support for our hypothesis. Except for amplified muscle afferent signals, a potential presynaptic sensitization at the dorsal horn may also potentially contribute to this increased glutamate Values are means Ϯ SE. Microinjection of all these antagonists or vehicle into the L4/L5 dorsal horn had no effect on basal blood pressure or HR in sham and CHF rats. KYN, kynurenate; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; AP5, DL-2-amino-5-phosphonovalerate. release in the spinal cord during exercise in CHF. This hypothesis requires further examination.
In the present study, we not only investigated neurotransmitter release in the spinal cord during exercise in CHF but also compared the cardiovascular response to exogenous glutamate injection into the dorsal horn between sham and CHF rats. Importantly, we found that direct microinjection of the same amount of glutamate into the spinal dorsal horn caused a greater pressor response in CHF rats than in sham rats. A major advantage of direct microinjection of the same amount of excitatory neurotransmitter into the dorsal horn is that it avoids a potential issue caused by different amount of transmitter release from presynaptic afferent endings to directly assess if postsynaptic neuronal sensitization of the EPR occurs in the dorsal horn in the CHF state. Therefore, our data strongly suggest that postsynaptic neurons in the dorsal horn of the lumbar spinal cord exhibit increased sensitivity in response to excitatory neurotransmitter release in the CHF state. The results of the present study suggest that spinal postsynaptic sensitization might be another potential contributor to the genesis of the exaggerated EPR in the CHF state.
Several excitatory and inhibitory neurotransmitters or neuromodulators have been identified to be involved in the modulation of the EPR at the level of the dorsal horn, including glutamate, substance P, serotonin, ACh, ␣ 2 -adrenergic receptors, opiates, vasopressin, and oxytocin (2, 12, 17, 19, 27) . Of these neurotransmitters or neuromodulators, the excitatory amino acid glutamate has been identified as a primary mediator of the EPR at the spinal cord level (8 -11, 38) . It has been demonstrated that administration of antagonists to excitatory amino acid receptors into this region attenuates the pressor reflex (8, 10, 38) . Consistent with these studies are the data from Hand et al. (8) showing that static muscle contraction increases the release of glutamate and aspartate into the dorsal horn of cats. A series of studies by Wilson and colleagues (9 -11) demonstrated that 1) static contraction increased glutamate release in the dorsal horn of anesthetized cats and 2) microdialysis of both NMDA receptor and non-NMDA-sensitive receptor antagonists into the dorsal horn attenuated pressor and tachycardia responses to either static contraction or passive stretch (a pure mechanical stimulus) in anesthetized cats. In addition, a parallel study by Adreani et al. (1) demonstrated a similar finding: that intrathecal blockade of both NMDA and non-NMDA receptors attenuated the exercise pressor reflex in decerebrate cats. Although these studies identify glutamate as a primary excitatory neurotransmitter mediating the EPR at the spinal cord level, the role of spinal glutamate as well as glutamatergic receptors in mediating the exaggerated EPR in the CHF state has not been investigated before. The present data show that 1) CHF rats have greater glutamate release in the dorsal horn during muscle contraction compared with sham rats, 2) protein expression of glutamatergic receptors is upregulated in the dorsal horn of CHF rats, 3) microinjection of exogenous glutamate into the dorsal horn of the lumbar spinal cord caused a greater pressor response in CHF rats than in sham rats, and 4) microinjection of several glutamate receptor antagonists (KYN, AP5, and CNQX) into L4/5 dorsal horns decreased the pressor response to static contraction in CHF rats to a greater extent than in sham rats. All of these findings indicate that increased glutamatergic input into the spinal cord is involved in the exaggerated EPR in the CHF state. It is of interest to note that an exaggerated gluatamatergic system has also been reported in higher structures with the central nervous system such as the paraventricular nucleus (15). It is not clear, however, which upstream factors or circulating humoral factors trigger this increased spinal glutamatergic activity in CHF. Furthermore, except for the spinal glutamatergic system, whether other neurotransmitter or neuromodulators and their respective receptors that have been reported to participate in the EPR at the level of the dorsal horn in spinal sensitization in CHF remains unknown. For example, we (35) recently identified GABA as an endogenous inhibitory neurotransmitter to tonically modulate the EPR at the level of the dorsal horn in the spinal cord of normal rats. Interestingly, GABA-mediated inhibition is also impaired in the paraventricular nucleus of rats with CHF (39) . Whether a spinal GABAergic system is altered and contributes to abnormal spinal sensitization of the EPR in CHF remains unknown and requires further study. Limitations. There are several potential limitations in this study that should be discussed. First, the carotid common arteries were ligated bilaterally to minimize cerebral bleeding during decerebration surgery. However, this procedure may, to some extent, impair the carotid sinus baroreflex. Therefore, using a decerebrated animal model potentially enlarges the differences between studies in animals and humans and compromises the applicability of the present findings to conscious humans. Second, microinjection of glutamate into the spinal cord in this study may activate a wide variety of afferents, including temperature receptors and nociceptors in addition to those mediating the EPR. Finally, although this study demonstrated increased spinal glutamatergic activity in CHF rats, we cannot determine the specific type of afferent that is primarily impacted by the increased expression of glutamate receptors.
In summary, the present study demonstrated that spinal cord dysfunction, independent of peripheral muscle afferent sensitization, contributes to the genesis of the exaggerated EPR in CHF. Furthermore, we provided evidence that an increased spinal glutamatergic system at least, in part, causes central sensitization of the EPR in CHF, which includes increased glutamate transmitter release in the dorsal horn during muscle contraction, the upregulated spinal glutamate receptors, and greater functional responses to microinjection of glutamate receptor agonist or antagonists into dorsal horn of the spinal cord in CHF. These findings may uncover new therapeutic targets for attenuating sympathoexcitation and improving exercise intolerance during physical activity in CHF patients.
